Phase 2
N=9
Reparixin in Pancreatic Islet Transplantation
Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus
Bottom Line
View on ClinicalTrials.gov: NCT01220856 ↗Enrolled (actual)
9
Serious AEs
44.4%
Results posted
Mar 2021
Primary outcome: Primary: The Percentage of Insulin-independent Patients Following Single Infusion Islet Cell Transplantation at Day 75 +/- 5 — 0; 0 percentage of patients
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Reparixin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Dompé Farmaceutici S.p.A
- Primary completion
- Apr 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Percentage of Insulin-independent Patients Following Single Infusion Islet Cell Transplantation at Day 75 +/- 5 |
0; 0 | — |
Summary
Inhibition of CXCL8 activity might represent a relevant therapeutic target to prevent injury occurring after pancreatic islet transplantation. Reparixin is a novel and specific inhibitor of CXCL8. This study is designed to explore the efficacy of reparixin in preventing graft dysfunction after islet transplantation in type 1 diabetes patients (T1D).
Eligibility Criteria
Inclusion criteria
- Ages 18-65 years, inclusive.
- Patients eligible for pancreatic islet transplantation based on local accepted practice and guidelines. This includes at least: a)clinical history compatible with T1D with insulin-dependence for >5 years; b) undetectable stimulated (arginine or MMTT) C-peptide levels ( 60 mL/min according to the Cockcroft-Gault formula (1976).
- Planned intrahepatic islet transplantation alone from a non-living donor with brain death.
- Planned infusion of 4000 to 7000 islet equivalent (IEQ)/kg body weight.
- Patients willing and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations.
- Patients given written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
Exclusion criteria
- Recipients of any previous transplant, except from recipients of a previous pancreatic islet transplantation that has failed, are off immunosuppression since at least 1 year and have negative anti-HLA.
- Recipients of islet from a non-heart beating donor.
- A body mass index >30 kg/m2 or patient weight 1 IU/kg/day.
- Pre-transplant HbA1c >11%.
- Patients with hepatic dysfunction as defined by increased ALT/AST > 3 x ULN and increased total bilirubin > 3mg/dL [>51.3 micromol/L]).
- Patients who receive treatment for a medical condition requiring chronic use of systemic steroids.
- Treatment with any anti-diabetic medication other than insulin within 4 weeks of transplant.
- Use of any investigational agent within 4 weeks of enrolment.
- Hypersensitivity to:
- ibuprofen or to more than one non steroidal anti-inflammatory drug
- medications belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib.
- Pregnant or breast-feeding women; unwillingness to use effective contraceptive measures (females and males).
Sites will comply with any additional exclusion criteria locally accepted, as per centre practice.
Data sourced from ClinicalTrials.gov (NCT01220856). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.